FI972430A0 - Fragment of monoclonal antibodies containing immunosuppressive activity - Google Patents

Fragment of monoclonal antibodies containing immunosuppressive activity

Info

Publication number
FI972430A0
FI972430A0 FI972430A FI972430A FI972430A0 FI 972430 A0 FI972430 A0 FI 972430A0 FI 972430 A FI972430 A FI 972430A FI 972430 A FI972430 A FI 972430A FI 972430 A0 FI972430 A0 FI 972430A0
Authority
FI
Finland
Prior art keywords
fragment
monoclonal antibodies
immunosuppressive activity
antibodies containing
containing immunosuppressive
Prior art date
Application number
FI972430A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI972430A (en
Inventor
Zoltan Nagy
Damir Vidovic
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI972430A0 publication Critical patent/FI972430A0/en
Publication of FI972430A publication Critical patent/FI972430A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI972430A 1994-12-07 1997-06-06 Fragments of a monoclonal antibody containing immunosuppressive activity FI972430A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35091594A 1994-12-07 1994-12-07
PCT/EP1995/004648 WO1996017874A1 (en) 1994-12-07 1995-11-25 Monoclonal antibody fragments having immunosuppressant activity

Publications (2)

Publication Number Publication Date
FI972430A0 true FI972430A0 (en) 1997-06-06
FI972430A FI972430A (en) 1997-06-06

Family

ID=23378740

Family Applications (1)

Application Number Title Priority Date Filing Date
FI972430A FI972430A (en) 1994-12-07 1997-06-06 Fragments of a monoclonal antibody containing immunosuppressive activity

Country Status (19)

Country Link
EP (1) EP0787151A1 (en)
JP (1) JP2001506122A (en)
CN (1) CN1168679A (en)
AR (1) AR002005A1 (en)
AU (1) AU4256096A (en)
BR (1) BR9509902A (en)
CA (1) CA2206471A1 (en)
CO (1) CO4480041A1 (en)
CZ (1) CZ172497A3 (en)
FI (1) FI972430A (en)
HU (1) HUT77342A (en)
IL (1) IL116228A0 (en)
MA (1) MA23739A1 (en)
NO (1) NO972522L (en)
PE (1) PE52996A1 (en)
PL (1) PL320610A1 (en)
TR (1) TR199501542A2 (en)
WO (1) WO1996017874A1 (en)
ZA (1) ZA9510195B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
WO2000012560A1 (en) * 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
DE60035337T2 (en) * 2000-05-12 2008-02-28 Gpc Biotech Ag Human peptides / proteins that cause or cause the killing of cells, including lymphoid tumor cells
EP1156062A1 (en) * 2000-05-12 2001-11-21 GPC Biotech AG Immunomodulatory human MHC class II antigen-binding peptides/proteins
US20030096285A1 (en) 2001-10-11 2003-05-22 Tso J. Yun Identifying anti-tumor targets or agents by lipid raft immunization and proteomics
JP3665324B2 (en) 2001-10-15 2005-06-29 麒麟麦酒株式会社 Anti-HLA-DR antibody
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
AU2011235328A1 (en) * 2010-04-01 2012-09-27 Immunomedics, Inc. Antibody-based depletion of antigen-presenting cells and dendritic cells
KR102647825B1 (en) * 2021-07-22 2024-03-14 서울대학교산학협력단 Anti-HLA-DP monoclonal antibody and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) * 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
WO1991010722A2 (en) * 1989-12-27 1991-07-25 Centocor, Inc. Chimeric immunoglobulin for cd4 receptors
SK285046B6 (en) * 1991-07-25 2006-05-04 Idec Pharmaceuticals Corporation Chimeric antibody, that specifically binds to human antigen, pharmaceutical composition in which the antibody is comprised, process of its production and using of it

Also Published As

Publication number Publication date
CZ172497A3 (en) 1997-10-15
MA23739A1 (en) 1996-07-01
BR9509902A (en) 1997-10-21
TR199501542A2 (en) 1996-07-21
PE52996A1 (en) 1996-12-12
AU4256096A (en) 1996-06-26
ZA9510195B (en) 1996-06-07
MX9704225A (en) 1997-09-30
PL320610A1 (en) 1997-10-13
WO1996017874A1 (en) 1996-06-13
HUT77342A (en) 1998-03-30
JP2001506122A (en) 2001-05-15
NO972522D0 (en) 1997-06-03
CA2206471A1 (en) 1996-06-13
CO4480041A1 (en) 1997-07-09
AR002005A1 (en) 1998-01-07
FI972430A (en) 1997-06-06
NO972522L (en) 1997-08-06
CN1168679A (en) 1997-12-24
IL116228A0 (en) 1996-03-31
EP0787151A1 (en) 1997-08-06

Similar Documents

Publication Publication Date Title
PT941121E (en) LIPOPILIZED PHARMACEUTICAL PREPARATIONS, STABLE, OF MONOCLONAL OR POLYCLONAL ANTIBODIES
PT719859E (en) ANTI-ALPHA MONOCLONAL ANTIBODY V-INTEGRINA
DK0941344T3 (en) Humanized anti-CD11a antibodies
IL128406A0 (en) Monoclonal antibodies
DK0837927T3 (en) Anti-CD80 antibodies
DE69319662D1 (en) Monoclonal antibodies to GP130 protein
DK666389A (en) MONOCLONAL ANTIBODY
DE69828154D1 (en) ANTI-ALPHAVBETA3 HUMANIZED MONOCLONAL ANTIBODIES
FI972430A0 (en) Fragment of monoclonal antibodies containing immunosuppressive activity
DE69738312D1 (en) HEPATITIS B MONOCLONAL ANTIBODIES
NO177311C (en) Anti-fucosylceramide monoclonal antibody
BR9606978A (en) Monoclonal anti-idiotype (ab2) antibodies and their uses
DK474189A (en) MONOCLONAL ANTIBODY
DK413389D0 (en) MONOCLONAL ANTIBODIES
GB9718911D0 (en) Monoclonal antibodies
ZA951113B (en) Tumor assosiated monoclonal antibody 123av16
DE69427850D1 (en) MONOCLONAL ANTIBODY AGAINST MUCOGLYCOPROTEIN
BR9709080A (en) Human anti-MP52 monoclonal antibody
GB9506425D0 (en) New uses of monoclonal antibodies
DE69324928D1 (en) MONOCLONAL ANTIBODY
SI0742795T1 (en) Immuno-stimulatory monoclonal antibodies
GB9615027D0 (en) Monoclonal antibodies
NO924137D0 (en) MONOCLONAL ANTI-IGM ANTIBODIES, THEIR PREPARATION AND USE, AND HYBRIDOMAS FOR THE PREPARATION OF THE SAME
GB9212074D0 (en) Monoclonal antibody
KR970034239U (en) Cover structure of cover